CRISPR-Csm for eukaryotic RNA knockdown and imaging without toxicity

No authors listed

Comment

No authors listed. Nat Biotechnol. 2023 Sep.

. 2023 Sep;41(9):1204-1205.

doi: 10.1038/s41587-023-01665-3.

No abstract available

Comment on

Precise transcript targeting by CRISPR-Csm complexes.
Colognori D, Trinidad M, Doudna JA. Colognori D, et al. Nat Biotechnol. 2023 Sep;41(9):1256-1264. doi: 10.1038/s41587-022-01649-9. Epub 2023 Jan 23. Nat Biotechnol. 2023. PMID: 36690762 Free PMC article.

Strategies and Methods for Improving the Efficiency of CRISPR/Cas9 Gene Editing in Plant Molecular Breeding.
Zhou J, Luan X, Liu Y, Wang L, Wang J, Yang S, Liu S, Zhang J, Liu H, Yao D. Zhou J, et al. Plants (Basel). 2023 Mar 28;12(7):1478. doi: 10.3390/plants12071478. Plants (Basel). 2023. PMID: 37050104 Free PMC article. Review.

1. Lennox, K. A. & Behlke, M. A. Mini-review on current strategies to knockdown long non-coding RNAs. J. Rare Dis. Res. Treat. 1, 66–70 (2016). A review article that describes the limitations of RNAi, especially for knockdown of long non-coding RNAs. - DOI
1. Ai, Y., Liang, D. & Wilusz, J. E. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells. Nucleic Acids Res. 50, e65 (2022). This paper reports the toxic side effects of Cas13’s trans-cleavage when used for RNA knockdown in eukaryotic cells. - DOI - PubMed - PMC
1. Kolesnik, M. V. et al. Deciphering the most complex prokaryotic immune system. Biochemistry (Moscow) 86, 1301–1314 (2021). This review article summarizes the type III CRISPR immune system. - DOI - PubMed
1. Staals, R. H. J. et al. RNA Targeting by the Type III-A CRISPR-Cas Csm Complex of Thermus thermophilus. Mol. Cell 56, 518–530 (2014). This paper characterizes the RNA targeting and cleavage activity of the Csm complex. - DOI - PubMed - PMC